Senate Special Committee on Aging Examines Drug Pricing

March 17, 2016
Contact: Ben Jenkins
Email: [email protected]

Senate Special Committee on Aging Examines Drug Pricing

Ahead of this morning's Senate Special Committee on Aging hearing on drug pricing, John Rother, executive director of the Campaign for Sustainable Rx Pricing issued the following statement:

"Today's hearing shows that fighting high prescription drug prices is truly a bipartisan battle. Companies are buying decades-old prescription drugs and jacking up prices on vulnerable patients. It's unconscionable. We need more transparency and competition in the prescription drug market to protect Americans from this appalling practice."

And, the problem of rising prescription drug prices is even more widespread than just Turing Pharmaceuticals or a few bad actors. Learn more about the startling pace of across-the-board price increases here in our fact sheet.

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.